Abstract
In 2003, the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure established a definition of a new category of BP levels called ‘prehypertension’ (preHT) that included individuals with a systolic BP of 120–139 mm Hg or a diastolic BP of 80–89 mm Hg. Patients with preHT were considered to be at increased risk for progression to hypertension and in individuals with BP in the range 130/80 to 139/89 mmHg the risk of developing hypertension was twice as high as in subjects with lower values. Still then there has been a large debate whether the introduction of preHT was based on evidence and as a consequence, it was fully justified. It has been suggested that the term prehypertension may in many subjects create anxiety and a need for unnecessary medical visits and examinations. This group of patients is also very heterogeneous and it has been pointed out that subdividing preHT group into individuals with normal BP and high normal BP would much better correspond to the continuum of BP risk for CV disease. Finally, despite some data suggesting the potential benefits of antihypertensive therapy in patients with preHT (high normal BP), there are still no hard evidences on the outcome reduction by giving antihypertensive drugs in these individuals.
Keywords: Blood pressure, cardiovascular risk, high normal blood pressure, hypertension, prehypertension, risk stratification.
Current Vascular Pharmacology
Title:Patients with Prehypertension - Do we have Enough Evidence to Treat them?
Volume: 12 Issue: 4
Author(s): Michalska Marta, Alberto Zanchetti, Nathan D. Wong, Jolanta Malyszko, Jacek Rysz and Maciej Banach
Affiliation:
Keywords: Blood pressure, cardiovascular risk, high normal blood pressure, hypertension, prehypertension, risk stratification.
Abstract: In 2003, the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure established a definition of a new category of BP levels called ‘prehypertension’ (preHT) that included individuals with a systolic BP of 120–139 mm Hg or a diastolic BP of 80–89 mm Hg. Patients with preHT were considered to be at increased risk for progression to hypertension and in individuals with BP in the range 130/80 to 139/89 mmHg the risk of developing hypertension was twice as high as in subjects with lower values. Still then there has been a large debate whether the introduction of preHT was based on evidence and as a consequence, it was fully justified. It has been suggested that the term prehypertension may in many subjects create anxiety and a need for unnecessary medical visits and examinations. This group of patients is also very heterogeneous and it has been pointed out that subdividing preHT group into individuals with normal BP and high normal BP would much better correspond to the continuum of BP risk for CV disease. Finally, despite some data suggesting the potential benefits of antihypertensive therapy in patients with preHT (high normal BP), there are still no hard evidences on the outcome reduction by giving antihypertensive drugs in these individuals.
Export Options
About this article
Cite this article as:
Marta Michalska, Zanchetti Alberto, Wong D. Nathan, Malyszko Jolanta, Rysz Jacek and Banach Maciej, Patients with Prehypertension - Do we have Enough Evidence to Treat them?, Current Vascular Pharmacology 2014; 12 (4) . https://dx.doi.org/10.2174/15701611113119990126
DOI https://dx.doi.org/10.2174/15701611113119990126 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Mineralocorticoid Receptor in Endothelial Physiology and Disease: Novel Concepts in the Understanding of Erectile Dysfunction
Current Pharmaceutical Design Targeting α7 Nicotinic Acetylcholine Receptor to Combat Inflammation in Cardio-Cerebral-Vascular Diseases
Current Drug Targets Phytochemistry and Pharmacological Update on Tetraterpenoids
The Natural Products Journal Effects of Blood Pressure Control in Cardiovascular Prevention
Current Pharmaceutical Design Current Perspectives on Hypertension in Asian Indians
Current Hypertension Reviews Pathophysiology of Cardiovascular Diseases and the Role of Vitamins, and Herbal Extracts in the Reduction of Cardiovascular Risks
Cardiovascular & Hematological Agents in Medicinal Chemistry Lifestyle Factors and Endothelial Function
Current Vascular Pharmacology Effects of Atorvastatin on Cerebral Blood Flow in Middle-Aged Adults at Risk for Alzheimer’s Disease: A Pilot Study
Current Alzheimer Research Nutraceuticals for Metabolic Syndrome Management: From Laboratory to Benchside
Current Vascular Pharmacology Mechanisms of Endothelial Dysfunction: Clinical Significance and Preventive Non-Pharmacological Therapeutic Strategies
Current Pharmaceutical Design Sodium Intake Recommendations: A Subject that Needs to be Reconsidered
Current Hypertension Reviews Abnormal Insulin Signaling: Early Detection of Silent Coronary Artery Disease-Erectile Dysfunction?
Current Pharmaceutical Design Phytochemical Therapies in Vascular Functioning: A Molecular Approach
Current Vascular Pharmacology Facing Up the ROS Labyrinth - Where To Go?
Current Vascular Pharmacology Is There an Association between Periodontitis and Hypertension?
Current Cardiology Reviews Treating Arterial Stiffness in Young and Elderly Patients with the Metabolic Syndrome
Current Pharmaceutical Design Management of the Metabolic Syndrome as a Strategy for Preventing the Macrovascular Complications of Type 2 Diabetes: Controversial Issues
Current Diabetes Reviews Salt-Sensitive Hypertension: Perspectives on Intrarenal Mechanisms
Current Hypertension Reviews Blood Pressure Management in Metabolic Syndrome
Current Hypertension Reviews Treatment Strategies for Fatty Liver Diseases
Reviews on Recent Clinical Trials